Measurement of nasal bone length at 11-14 weeks of pregnancy and its potential role in Down syndrome risk assessment

被引:79
作者
Orlandi, F
Bilardo, CM
Campogrande, M
Krantz, D
Hallahan, T
Rossi, C
Viora, E
机构
[1] Ctr Diagnosi Prenatale, I-90141 Palermo, Italy
[2] Div Ost Gin Osped S Anna, Turin, Italy
[3] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[4] NTD Labs, Huntington Stn, New York, NY USA
关键词
Down syndrome; free beta-hCG; nasal bone; PAPP-A; pregnancy; screening;
D O I
10.1002/uog.167
中图分类号
O42 [声学];
学科分类号
070206 ; 082403 ;
摘要
Objectives To assess the feasibility of measuring nasal bone length in first-trimester pregnancy and to confirm if the absence of a fetal nasal bone is a marker for Down syndrome. Methods Fetal nasal bone assessment was attempted in 1089 consecutive singleton pregnancies between 11 and 14 weeks' gestation. All ultrasound examinations were performed transabdominally in three separate centers. If the nasal bone was present, nasal bone length was measured. Results Nasal bone assessment was successfully achieved in 1027 of 1089 (94.3%) ultrasound examinations. Within this group nasal bone was absent in 10 of 1000 (1.0%) unaffected cases, 10 of 15 (66.7%) Down syndrome cases and 5 of 12 (41.7%) cases with other pathological conditions. Regression analysis showed a significant increase (P < 0.0001) in nasal bone length from 2.48 mm at a crown-rump length of 45 mm to 3.12 mm at a crown-rump length of 84 mm. The nasal bone length in the five cases of Down syndrome in which the nasal bone was present was less than the median measurement of unaffected cases. Using modeling, the combination of nasal bone with maternal age, nuchal translucency, free beta-human chorionic gonadotropin (hCG) and pregnancy associated plasma protein-A (PAPP-A) achieved a detection rate of 95% with a false-positive rate of 2.9%. At a fixed 1% false-positive rate, the detection rate was 9.1%. Conclusions Absence of the nasal bone can be used as a marker for Down syndrome in the first trimester of pregnancy. Inclusion of the nasal bone in the current first-trimester screening protocol along with nuchal translucency, free beta-hCG and PAPP-A can achieve high detection at a very low false-positive rate. Large datasets are needed to confirm whether the measurement of nasal bone length provides additional benefits beyond the assessment of the presence or absence of the nasal bone. Copyright (C) 2003 ISUOG. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:36 / 39
页数:4
相关论文
共 18 条
[1]   Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening - A prospective study [J].
Benattar, C ;
Audibert, F ;
Taieb, J ;
Ville, Y ;
Roberto, A ;
Lindenbaum, A ;
Frydman, R .
FETAL DIAGNOSIS AND THERAPY, 1999, 14 (02) :112-117
[2]   First trimester screening for Down's syndrome using maternal serum PAPP-A and free β-hCG in combination with fetal nuchal translucency thickness [J].
Biagiotti, R ;
Brizzi, L ;
Periti, E ;
d'Agata, A ;
Vanzi, E ;
Cariati, E .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1998, 105 (08) :917-920
[3]   One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies [J].
Bindra, R ;
Heath, V ;
Liao, A ;
Spencer, K ;
Nicolaides, KH .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2002, 20 (03) :219-225
[4]  
Cicero S, 2002, J Matern Fetal Neonatal Med, V11, P400, DOI 10.1080/713605572
[5]   Nasal bone hypoplasia in trisomy 21 at 15-22 weeks' gestation [J].
Cicero, S ;
Sonek, JD ;
McKenna, DS ;
Croom, CS ;
Johnson, L ;
Nicolaides, KH .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2003, 21 (01) :15-18
[6]   Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study [J].
Cicero, S ;
Curcio, P ;
Papageorghiou, A ;
Sonek, J ;
Nicolaides, K .
LANCET, 2001, 358 (9294) :1665-1667
[7]   Time for total shift to first-trimester screening for Down's syndrome [J].
Cuckle, H .
LANCET, 2001, 358 (9294) :1658-1659
[8]  
De Biasio P, 1999, PRENATAL DIAG, V19, P360, DOI 10.1002/(SICI)1097-0223(199904)19:4<360::AID-PD556>3.0.CO
[9]  
2-U
[10]  
de Graaf IM, 1999, PRENATAL DIAG, V19, P458, DOI 10.1002/(SICI)1097-0223(199905)19:5<458::AID-PD569>3.0.CO